Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBITDA: 2023-2025

Historic EBITDA for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$51.1 million.

  • CG Oncology's EBITDA fell 80.70% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.1 million, marking a year-over-year decrease of 87.68%. This contributed to the annual value of -$114.7 million for FY2024, which is 106.80% down from last year.
  • Per CG Oncology's latest filing, its EBITDA stood at -$51.1 million for Q3 2025, which was down 4.90% from -$48.7 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's EBITDA peaked at -$9.7 million during Q1 2023, and registered a low of -$51.1 million during Q3 2025.
  • In the last 3 years, CG Oncology's EBITDA had a median value of -$25.9 million in 2024 and averaged -$28.4 million.
  • Data for CG Oncology's EBITDA shows a maximum YoY crashed of 131.14% (in 2024) over the last 5 years.
  • CG Oncology's EBITDA (Quarterly) stood at -$19.4 million in 2023, then crashed by 96.58% to -$38.0 million in 2024, then plummeted by 80.70% to -$51.1 million in 2025.
  • Its EBITDA was -$51.1 million in Q3 2025, compared to -$48.7 million in Q2 2025 and -$42.2 million in Q1 2025.